Stefan Niewiesk DVM, PhD
General Research InterestParamyxovirus pathogenesis, vaccination (in the presence of maternal antibodies), T cell tumors, adult T cell leukemia, oncolytic therapy
Research DescriptionOne of the interests of the Niewiesk laboratory is the use of measles vaccine virus as oncolytic therapy to cure T cell leukemias. We use the mouse model of adult T cell leukemia to study the interaction between tumor cells, microenviroment and virus. One aspect of this research is how to use genetically improved viruses to combat leukemia and how to combine viral oncolytic therapy with other conventional or experimental therapies.
Transinstitutional WorkParticipation in Viral Oncology program of the CCC at The Oio State University and the program project grant "Retrovirus Models of Lymphocyte Transformation and Disease" with participants from Washington University in St. Louis. Collaboration on vaccination and antivirals with Emory University, Cornell University and various companies.
Yin H, Kannian P, Dissinger N, Haines R, Niewiesk S, Green PLHuman T-cell leukemia virus type 2 antisense viral protein 2 is dispensable for in vitro immortalization but functions to repress early virus replication in vivo.J Virol 86(16) 8412-21 8/1/2012
© The Ohio State University